Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
Adolescent
Adult
Aged
Asthma
/ diagnosis
Bronchodilator Agents
/ administration & dosage
Cross-Over Studies
Double-Blind Method
Drug Combinations
Female
Fluticasone-Salmeterol Drug Combination
/ administration & dosage
Humans
Indans
/ administration & dosage
Male
Middle Aged
Mometasone Furoate
/ administration & dosage
Quinolones
/ administration & dosage
Young Adult
Asthma
Glycopyrronium
Indacaterol
Mometasone Furoate
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
15 Apr 2020
15 Apr 2020
Historique:
received:
23
12
2019
accepted:
01
04
2020
entrez:
17
4
2020
pubmed:
17
4
2020
medline:
30
1
2021
Statut:
epublish
Résumé
Indacaterol (IND; 150 μg), glycopyrronium (GLY; 50 μg) and mometasone furoate (MF; 160 μg [high-dose ICS] and 80 μg [medium-dose ICS]) have been formulated as a once-daily (o.d.) fixed-dose combination treatment delivered via the Breezhaler® device for the treatment of patients with asthma. In this randomized (n = 116), double-blind, double-dummy, active comparator-controlled, three-period cross-over study we evaluated the benefit of o.d. IND/GLY/MF versus twice daily (b.i.d.) salmeterol/fluticasone propionate combination (SFC; 50/500 μg; high-dose ICS) treatment (NCT03063086). Overall, 107 patients completed the study. The study met its primary objective by demonstrating superiority of o.d. IND/GLY/MF at medium and high-dose ICS over b.i.d. SFC (high-dose ICS) in peak FEV
Identifiants
pubmed: 32295593
doi: 10.1186/s12931-020-01349-5
pii: 10.1186/s12931-020-01349-5
pmc: PMC7160900
doi:
Substances chimiques
Bronchodilator Agents
0
Drug Combinations
0
Fluticasone-Salmeterol Drug Combination
0
Indans
0
Quinolones
0
indacaterol acetate-mometasone furoate drug combination
0
Mometasone Furoate
04201GDN4R
Types de publication
Clinical Trial, Phase II
Comparative Study
Letter
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
87Références
Allergy Asthma Immunol Res. 2017 Sep;9(5):386-393
pubmed: 28677351
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
NPJ Prim Care Respir Med. 2014 Jun 12;24:14009
pubmed: 24921985
Lancet. 2019 Nov 9;394(10210):1737-1749
pubmed: 31582314
Am J Respir Crit Care Med. 2004 Oct 15;170(8):836-44
pubmed: 15256389
Respir Med. 2016 Aug;117:198-206
pubmed: 27492532